Oil prices fell sharply after reports emerged that U.S. Vice President JD Vance contacted Iranian officials to restart peace negotiations, easing fears of supply disruptions from Middle East conflicts. Brent crude dropped 1.23% to $113.9 per barrel, and U.S. West Texas Intermediate crude fell 1.42% to $101.32 per barrel. Despite some diplomatic progress, significant hurdles remain as Iran rejected some proposals, though it remains open to talks. Investors remain cautious due to ongoing risks of attacks and potential U.S. military action, keeping prices elevated and impacting inflation and monetary policy outlooks.
Oil prices fall as renewed U.S.-Iran peace efforts ease supply fears, with Pluang market data as of Oct 29, 2026 12:51 WIB showing breadth among 79 priced Energy-sector US stocks where 55 rose and 22 fell. Notable movers include UGP at USD 6.13 with a 1-day change of -4.22%, PTEN at USD 12.73 up 4.17%, and VAL at USD 101.85 rising 3.71%. The most notable figure is PTEN's 4.17% increase.
TGS ASA announced that its shares will be traded ex-dividend at NOK 1.45 per share starting October 29, 2026. This means investors buying the stock from this date will not receive the upcoming dividend payment. The dividend distribution follows appro...
DNO ASA, a Norwegian oil and gas company, announced a cash dividend of NOK 0.375 per share to be paid around November 17, 2026. Shareholders registered by November 9, 2026, will receive the dividend, with shares trading ex-dividend starting November ...
A post on X from The Bitcoin Historian account attributed to Fidelity Investments suggests investors increasingly view Bitcoin as a safe-haven asset and hints at renewed upward momentum. It also referenced a previous post predicting Bitcoin could rea...
Bitcoin long-term holders decreased their supply by 22% in the week ending October 29, dropping from 310,000 BTC to 240,000 BTC over 30 days. Their unrealized profit margin also narrowed slightly, with the MVRV ratio falling from 1.67 to 1.65, indica...
Johnson & Johnson reported Q3 revenue of $25.4 billion, driven by a 7.9% operational growth in its Innovative Medicine segment, while its MedTech division grew only 2.5%. The company raised its 2026 revenue guidance slightly to $101.2 billion, up fro...
